[{"address1": "171 Oyster Point Boulevard", "address2": "Suite 400", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 489 9000", "website": "https://www.surrozen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig C. Parker M.B.A.", "age": 62, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 825320, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles  Williams", "age": 44, "title": "CFO, COO & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 611028, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Li  Yang Ph.D.", "age": 55, "title": "Executive Vice President of Research", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 535463, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. K. Christopher  Garcia Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roeland  Nusse Ph.D.", "age": 74, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1950, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Calvin  Kuo M.D., Ph.D.", "title": "Co-Founder & Member of Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Esther  Jhun", "title": "Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 14.35, "open": 14.23, "dayLow": 14.0, "dayHigh": 15.5, "regularMarketPreviousClose": 14.35, "regularMarketOpen": 14.23, "regularMarketDayLow": 14.0, "regularMarketDayHigh": 15.5, "forwardPE": -1.7570901, "volume": 56260, "regularMarketVolume": 56260, "averageVolume": 35200, "averageVolume10days": 32730, "averageDailyVolume10Day": 32730, "marketCap": 46309648, "fiftyTwoWeekLow": 6.0, "fiftyTwoWeekHigh": 16.19, "priceToSalesTrailing12Months": 4.6309648, "fiftyDayAverage": 10.55688, "twoHundredDayAverage": 10.101035, "currency": "USD", "enterpriseValue": 16836800, "floatShares": 1131672, "sharesOutstanding": 3249800, "sharesShort": 45377, "sharesShortPriorMonth": 23713, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.0139999995, "heldPercentInsiders": 0.0167, "heldPercentInstitutions": 0.77182, "shortRatio": 0.91, "shortPercentOfFloat": 0.0188, "impliedSharesOutstanding": 3249800, "bookValue": 1.756, "priceToBook": 8.115034, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -44438000, "trailingEps": -16.94, "forwardEps": -4.45, "lastSplitFactor": "1:15", "lastSplitDate": 1702512000, "enterpriseToRevenue": 1.684, "enterpriseToEbitda": -0.673, "52WeekChange": 0.38379943, "SandP52WeekChange": 0.25443196, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SRZN", "underlyingSymbol": "SRZN", "shortName": "Surrozen, Inc.", "longName": "Surrozen, Inc.", "firstTradeDateEpochUtc": 1610375400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f300e438-31d2-353a-a98a-8e2cc4bb3308", "messageBoardId": "finmb_401948183", "gmtOffSetMilliseconds": -18000000, "currentPrice": 14.25, "targetHighPrice": 33.0, "targetLowPrice": 33.0, "targetMeanPrice": 33.0, "targetMedianPrice": 33.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 31012000, "totalCashPerShare": 9.607, "ebitda": -25022000, "totalDebt": 1527000, "quickRatio": 7.06, "currentRatio": 7.4, "totalRevenue": 10000000, "debtToEquity": 26.945, "revenuePerShare": 3.804, "returnOnAssets": -0.32645, "returnOnEquity": -1.73593, "grossMargins": -1.723, "ebitdaMargins": -2.5022001, "operatingMargins": 0.1232, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]